• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioClinica Buys Tourtellotte Solutions for $2.1M

BioClinica Buys Tourtellotte Solutions for $2.1M

September 17, 2009
CenterWatch Staff

BioClinica’s September buying spree continued this week with the announcement that the Newtown, Pa.-based contract research organization (CRO) had purchased technology company Tourtellotte Solutions for $2.1 million in cash, plus additional payments in the form of up to $3.2 million in cash and 350,000 shares of BioClinica common stock if certain milestones are met.

Tourtellotte, a technology company based in Wayland, Mass., with additional operations in Bhubaneswar, India, provides interactive voice response (IVR) and interactive web response (IWR) software applications and consulting services to support drug development. The company’s software is currently being used in more than 150 active clinical trials, according to BioClinica.

“Tourtellotte brings a leading edge technology platform and a proven development and support team to BioClinica. These additions expand the ways in which we can work with our global biopharmaceutical clients to improve the overall clinical trial process,” said BioClinica president and CEO Mark Weinstein in a statement. “The acquisition of Tourtellotte further demonstrates how BioClinica is executing on our strategy of adding complementary products that deliver more efficient clinical trials.”

Tourtellotte Solutions generated approximately $3.9 million in revenue in 2008, and BioClinica estimates that the company will generate approximately $5 million in revenue for the full year 2009 on a stand-alone basis. For the remainder of 2009, BioClinica estimates that Tourtellotte will contribute approximately $1.2 million in revenue and a small amount of operating income to the CRO’s financials.

As part of the acquisition, Ed Tourtellotte, president of Tourtellotte Solutions, will join BioClinica as vice president, product innovation, and his team will become a part of BioClinica’s eClinical division.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing